



Detection of Extended Spectrum Beta-Lactamase Producing *Escherichia coli* from Urinary Tract Infection in General Hospital, Minna

Nasiru U. Adabara¹, Naimat D. Bakinde¹, Sherifat O. Enejiyon^{1*}, Tijani Salami² and Doosuur Iorzua¹

¹Department of Microbiology, School of Life Sciences, Federal University of Technology, Minna, Nigeria

Email: nasiru.adabara@futminna.edu.ng; dayonaimat@gmail.com;
*enejiyon.sherifat@futminna.edu.ng; doosuur@gmail.com

²University Health Service Unit, Federal University of Technology, Minna, Nigeria,
Email: salamson79@yahoo.com

*Corresponding author

Received 9 May 2020, Revised 20 Aug 2020, Accepted 31 Aug 2020, Published Oct 2020

Abstract

Possession of virulence factors such as extended spectrum beta lactamase (ESBL) by pathogens generally exacerbates morbidity as well as increases healthcare costs. This study determined the production of ESBL among *Escherichia coli* isolated from the urinary tracts of subjects attending General Hospital, Minna, Nigeria. One hundred and fifty (150) urine samples were collected from subjects and cultured on CLED agar for the isolation of *E. coli*. Antibiotic susceptibility testing was done using Kirby Bauer disk diffusion method, while the phenotypic identification of ESBL-producing strains was carried out using double disk synergy test. All results were interpreted based on Clinical and Laboratory Standards Institute guidelines. In all, 26 (17.33%) out of the 150 urine samples cultured had *E. coli*; out of which 23 (88.5%) were subsequently found to be ESBL producers. Among the *E. coli* isolates, high rates of antibiotic-resistance was observed against nalidixic acid (100%), cefdinir (88.4%), cefotaxime (84.6%) and cefpodoxime (84.6%), while remarkable sensitivity to tarivid (46.1%), ciprofloxacin (38.4%) and gentamicin (34.6%) was also detected. This study has established the involvement of ESBL-producing *E. coli* in urinary tract infections in the study area. Rational prescription of antibiotics against pathogens generally is highly recommended to halt the spread of resistance.

Keywords: Beta-Lactamase, Extended spectrum, Infection, Prescription, Resistance.

Introduction

Urinary tract infection (UTI) which results from the microbial infections of either the lower or the upper urinary tracts known as acute cystitis and pyelonephritis, respectively, remains a public health challenge worldwide (Gupta et al. 2017). UTI is the commonest bacterial infection among females and males. It is expected that about 35% of healthy women experience warning signs of UTIs (Nithyalakshmi 2014). The

incidence is far higher in women than men due to the proximity of the vagina to the anus which provides for easy contamination with faecal flora and also as a consequence of pregnancy (Yadav and Prakash 2017). The incidence of UTI in developing countries is quite high and this may not be unconnected with the dearth of social and sanitary infrastructures like toilets and pipe borne water, poor sanitation, ignorance and poverty. About 95% of cases of UTI worldwide have

bacterial aetiology (Ramesh et al. 2008) out of which only about 15–20% are caused by Gram positive bacteria making the Gram negative bacteria as the main aetiology of bacterial UTI (Babu et al. 2014). Among the Gram negative bacteria frequently implicated in UTI, *E. coli* is the most frequently encountered.

In recent years, the threat of antibiotic resistance among *E. coli* and other *Enterobacteriaceae* has generated great concern within the medical community. This development is especially frightening because of a concurrent significant increase in community-acquired infections caused by extended-spectrum β -lactamase (ESBL) or AmpC β -lactamase-producing *E. coli* strains which have also been observed worldwide (Simner et al. 2011). In addition to being resistant to most cephalosporins, these *E. coli* strains are often co-resistant to fluoroquinolones and other first-line antibiotics. For patients infected with these drug-resistant *E. coli* strains, adequate antibacterial therapy easily gets delayed as treatment options for infections caused by these organisms such as urinary tract infections are often limited and the therapy complicated (Voets et al. 2012, Lin et al. 2019).

Extended-spectrum β -lactamases (ESBLs) are enzymes produced by certain bacteria which confer on them the ability to resist most common β -lactam antibiotics such as penicillins, cephalosporins and monobactam (Picozzi et al. 2014, Ghafourian et al. 2015). Among the ESBL producing *Enterobacteriaceae*, *E. coli* has emerged again as the most frequently encountered.

Ever since the discovery of the first plasmid mediated β lactamase among *E. coli* in 1965, ESBL producing *E. coli* has increased worldwide and it is now one of the most common causes of hospital-acquired infections with increased morbidity and mortality rate (Kim et al. 2017). Community acquired urinary tract infections caused by extended spectrum β lactamase producing

organisms is on the rise throughout the world (Dayan et al. 2013). Increasing evidence has suggested that ESBL producing organisms commonly retain resistance factors against other classes of antibiotics, especially the quinolones and aminoglycosides. This could be attributed to the association of multi drug resistance in ESBL producing isolates (Kumar et al. 2014). There are known risk factors such as age (<1 year), children on uroprophylaxis, recurrent UTI and recent antibiotic usage which can predict the occurrence of the ESBL producers (Balasubramanian et al. 2018).

The rapid identification and characterization of resistant organisms, especially ESBL producing organisms that are evidently associated with greater morbidity and mortality, is therefore an important assignment for laboratories in the fight against microbial resistance. This study attempted to isolate and identify ESBL producing *E. coli* from subjects with urinary tract infections in Minna.

Materials and Methods

Study area

Minna is a city in North central region of Nigeria with an estimated population of 304,113 in 2017.

Ethical consideration

Ethical clearance was obtained from the Ethics and Research Committee of the General Hospital Minna, Niger State, while samples collection from the participants was based on informed consent.

Inclusion and exclusion criteria

Patients with medical history of nausea, painful micturition, haematuria, pelvic inflammation, pain or pressure in back or lower abdomen were included with the exclusion of patients who refused to give their consent.

Collection of samples

Urine samples were collected from a total of 150 patients attending General Hospital Minna, Niger State, Nigeria in sterile sample containers and transported immediately to the Microbiology Laboratory of the Federal University of Technology Minna, Niger State for processing.

Isolation and identification of *E. coli* from urine

Each urine sample collected was aseptically inoculated on Cystine-Lactose-Electrolyte Deficient (CLED) agar using sterile loop and incubated at 37 °C for 24 hours. Distinct colonies on growth from the primary culture were sub-cultured on MacConkey agar and further incubated at 37 °C for another 24 hours to obtain pure culture. Pure cultures obtained were stored in slant bottles and kept in the refrigerator for further tests. The identification of *E. coli* isolates was done using morphological appearance of the colonies, Gram stain reactions and biochemical properties.

Antimicrobial susceptibility testing (AST)

The modified Kirby Bauer disk diffusion method was used to determine the susceptibility of the isolates to the commonly prescribed antibiotics in the General Hospital, Minna, namely ceftazidime (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), cefixime (5 µg), cefpodoxime (10 µg), cefdinir (5 µg), ciprofloxacin (5 µg), tarvid (5 µg), gentamicin (10 µg) and nalidixic acid (30 µg). The antibiotic disks which were of analytical grade were obtained from high media laboratories. A 5 ml suspension of each isolate was prepared in sterile normal saline to a turbidity of 0.5 McFarland standard (10^8 cfu/mL). The suspension was then inoculated aseptically over the surface of Mueller-Hinton agar plate and antimicrobial disks were placed on the plates using sterile

forcep. The plates were incubated at 37 °C for 24 hours. The diameter of zones of inhibition were measured and interpreted according to CLSI standard interpretation chart (CLSI 2018).

Phenotypic screening for the production of extended spectrum beta lactamase enzymes

Screening for the production of Extended Spectrum Beta Lactamases was done using double disc synergy test (DDST). A disk containing amoxicillin + clavulanic acid (30 µg/10 µg) was placed centrally on a Mueller-Hinton agar plate previously swabbed with the test isolate, while third-generation cephalosporin antibiotics: ceftazidime (30 µg) and cefotaxime (30 µg) disks were placed 20 mm around the amoxicillin + clavulanic acid disk. The plates were incubated at a temperature of 37 °C overnight. A clear extension of the edge of the zone of inhibition of cephalosporins toward the amoxicillin-clavulanic acid disc was interpreted as positive result for ESBL production.

Results

Prevalence of UTI among suspected respondents

Out of the 150 samples screened comprising 63 and 87 males and females, respectively, 26 (17.3%) were positive for *E. coli* with males having 8 (12.7%) against females 18 (20.7%) as shown in Table 1. The distribution of infections on the basis of age revealed the highest prevalence for *E. coli* among age group 11-20 (24.2%), followed by 51 and above (16.7%). Age groups 31-40, 21-30, and 0-10 had prevalence rates of 16.0%, 15.6%, and 13.3%, respectively, while the least prevalence was observed in the age group 41-50 (12.0%).

Table 1: Gender distribution for *E. coli* isolates

Gender	Number of samples	Number of positive samples	Percentage (%)
Female	87	18	20.7
Male	63	8	12.7

Table 2: Age distribution for *E. coli* isolates

Age (Years)	Number of samples	Number of positive samples	Percentage (%)
0-10	15	2	13.3
11-20	33	8	24.2
21-30	45	7	15.6
31-40	25	4	16.0
41-50	18	3	12.0
51 and above	14	3	16.7

Antibiotic susceptibility pattern of the *E. coli* isolates

The isolates mostly resisted nalixidic acid (100.0%), cefdinir (88.4%), cefpodoxime (84.6%), cefotaxime (84.6%), cefixime

(80.7%) and ceftriaxone (76.9%) but exhibited varying sensitivity to tarivid (46.1%), ciprofloxacin (38.4%) and gentamycin (34.6%). The observations are presented in Table 3.

Table 3: Antibiotic susceptibility pattern of *E. coli* isolates

Antibiotics	Sensitive	Percentage of isolates (%)	Intermediate	Resistance
Ceftazidime	19.2	19.2	19.2	61.5
Ceftriaxone	15.3	7.6	7.6	76.9
Cefotaxime	3.8	11.5	11.5	84.6
Cefixime	7.6	11.5	11.5	80.7
Cefpodoxime	7.6	7.6	7.6	84.6
Cefdinir	7.6	3.8	3.8	88.4
Ciprofloxacin	38.4	19.2	19.2	42.3
Gentamicin	34.6	7.6	7.6	56.9
Tarivid	46.1	15.3	15.3	38.4
Nalixidic acid	0.0	0.0	0.0	100.0

Presence of ESBL in *E. coli* isolates

Out of the 26 *E. coli* isolates that exhibited resistance against the third generation cephalosporin, 23 (88.5%) were ESBL producers, while 3 (11.5%) were non-ESBL producers as presented in Table 4.

Table 4: Presence of ESBL in *E. coli* Isolates

Isolates	Number of isolates (%)
ESBL-producer	23 (88.5)
Non-ESBL-producer	3 (11.5)
Total	26

Discussion

In this study, a relatively high recovery of *E. coli* isolates was observed among the 150 urine sample screened. This observation is clearly in agreement with the prevailing reports from Mansour et al. (2009) and Alanazi et al. (2018) that the organism is among the most frequently isolated in urine samples. This observation may not be unconnected with the presence of *E. coli* in stool being a resident flora in the gastrointestinal tract as a result of which it does not require sexual activity for its

transmission to occur. It was also observed that the female subjects had higher carriage rate (20.7%) of *E. coli* than males (12.7%). This is in agreement with the earlier findings of Alqasim et al. (2018) and Yadav and Prakash (2017), in which higher carriage rates of *E. coli* were reported in females compared to the males. High prevalence of UTI in women has been generally attributed to the closeness of the urethra to the anus and their complex physiology especially during gestational periods. Certain forms of contraceptives used by females are also believed to encourage the occurrence of UTI. An age dependent distribution of the prevalence of *E. coli* infection revealed that the age groups 11-20 (24.2%) and 41-50 (12.0%) years had the highest and the lowest rates, respectively.

The isolates exhibited varying antibiotic resistance against the antibiotics tested. The highest resistance was recorded in the order: nalixidic acid (100%), cefdinir (88.4%), cefotaxime (84.6%) cefpodoxime (84.6%), and cefixime (80.7%). The highest antibiotic sensitivity was observed with tarivid (46.1%), ciprofloxacin (38.4%) and gentamicin (34.6%). In similar studies, Yadav and Prakash (2017) observed the highest resistance with ceftriaxone (67.47%), ceftazidime (63.41%) and nalidixic acid (73.98%), Fernando et al. (2017) observed the highest resistance with ceftriaxone (100%), ceftazidime (100%) and ciprofloxacin (90.10%), while Hassuna et al. (2020) record 100% resistance to ceftazidime, cefotaxime and cefpodoxime and susceptibility to gentamycin and ciprofloxacin at 73.75% and 86.25%, respectively. The high rate of resistance in this study was ascertained to be due to the production extended spectrum beta lactamase by almost all the *E. coli* isolates.

Out of the 26 *E. coli* isolates, 23 (88.5%) were ESBL-producers, while 3 (11.5%) were non-ESBL producers. Singh et al. (2016), Datta et al. (2014), Kim et al. (2017) and Rajabnia et al. (2019) reported prevalence of

ESBL-producer as 46.87%, 82.6%, 21.4% and 37.11%, respectively. In Kano, North-western Nigeria, a prevalence of 15.4% for ESBL producers was earlier reported (Tijjani et al. 2012). The differences in the results could be due to different numbers of samples, recent antibiotic usage and hospitalization. However, the findings of this study even though limited by its restriction to a single hospital, has further lend credence to the growing concerns about the spread of ESBL producing bacteria, especially *E. coli* within hospital settings. In a study carried out in Spain, a rise in ESBL by *E. coli* producers from less than 0.36% to 4.8% was recorded only within seven years from 1995 to 2002 (Romero et al. 2005).

Conclusion

While the findings of this study are inadequate to make a generalized statement because of its restriction to a single hospital, a dramatic increase in the prevalence of ESBL-producing *E. coli* was however observed. Given its consequences which include longer hospitalization, increased hospital expenses, reduced rates of therapeutics responses and higher mortality, a national surveillance of their prevalence and antibiotic susceptibility pattern as well as strict compliance with antibiotics policy and rational antibiotics usage are strongly recommended.

References

- Alanazi MQ, Alqahtani FY and Aleanizy FS 2018 An evaluation of *E. coli* in urinary tract infection in Emergency Department at KAMC in Riyadh, Saudi Arabia: retrospective study. *Ann. Clin. Microbiol. Antimicrob.* 17(1): 3.
- Alqasim A, Abu Jaffal AA and Alyousef AA 2018 Prevalence of multidrug resistance and extended spectrum β -lactamase carriage of clinical uropathogenic *Escherichia coli* in Riyadh, Saudi Arabia. *Int. J. Microbiol.* 2018: 3026851.

- Babu V, Narasigam A, Ragavan RM, Manoharan SK and Paul A 2014 Multidrug resistant *Escherichia coli* and *Klebsiella pneumoniae* from the urinary tract infections with special reference to extended spectrum β -lactamase (ESBL) production. *Int. J. Biol. Pharm. Res.* 5(1): 66-70.
- Balasubramanian S, Kuppaswamy D, Padmanabhan S, Chandramohan V and Amperayani S 2018 Extended spectrum beta-lactamase producing community acquired urinary tract infections in children; chart review of risk factors. *J. Glob. Infect. Dis.* 10(2): 222-225.
- Clinical and Laboratory Standards Institute (CLSI) 2018 Performance standards for antimicrobial susceptibility testing: twenty-eight informational supplement (M100-S28). USA: CLSI: Wayne, PA. 2018.
- Datta P, Gupta V, Sidhu S and Chander J 2014 Community urinary tract infection due to ESBL producing *E. coli*: epidemiology and susceptibility to oral antimicrobials including Mecillinam. *Nepal J. Med. Sci.* 3: 5-7.
- Dayan N, Dabbah H, Weissman I, Aga I, Even L and Glikman D 2013 Urinary tract infections caused by community-acquired extended-spectrum β -lactamase-producing and nonproducing bacteria: a comparative study. *J. Pediatr.* 163(5):1417-1421.
- Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, Silva FH and Premaratna R 2017 Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern-a hospital based cross sectional study. *BMC Infect. Dis.* 17(1): 138.
- Ghafourian S, Sadeghifarh N, Soheili S, and Sekawi Z. 2015 Extended spectrum beta-lactamases: definition, classification and epidemiology. *Curr. Issues Mol. Biol.* 17:11-22.
- Gupta K, Grigoryan L and Trautner B 2017 Urinary tract infection. *Ann. Intern. Med.* 167(7): ITC49-ITC64.
- Hassuna NA, Khairalla AS, Farahat EM, Hammad AM and Abdel-Fattah M 2020 Molecular characterization of extended spectrum β lactamase-producing *E. coli* recovered from community-acquired urinary tract infections in Upper Egypt. *Sci. Rep.* 10(1): 1-8.
- Kim YH, Yang EM and Kim CJ 2017 Urinary tract infection caused by community-acquired extended-spectrum β -lactamase-producing bacteria in infants. *J. Ped. (Rio J)*. 93: 260-266.
- Kumar D, Singh AK, Ali RM and Chander Y 2014 Antimicrobial susceptibility profile of extended spectrum β -lactamase (ESBL) producing *Escherichia coli* from various clinical samples. *Infect. Dis.: Res. Treatment* 7: IDRT-S13820.
- Lin W, Huang Y, Wang J, Chen Y and Chan S 2019 Prevalence of and risk factor for community onset third-generation cephalosporin-resistant *Escherichia coli* bacteremia at a Medical center in Tairan. *BMC Infect. Dis.* 19: 245.
- Mansour A, Mahdinezhad M and Pourdangchi Z 2009 Study of bacteria isolated from urinary tract infections and determination of their susceptibility to antibiotics. *Jundishapur J. Microbiol.* 2(3): 118-123.
- Nithyalakshmi J 2014 Bacterial profile and antibiogram pattern of UTI in pregnant women at tertiary care teaching hospital. *Int. J. Pharm. Biosci.* 5(4): B201-B207.
- Picozzi SC, Casellato S, Rossini M, Paola G, Tejada M, Costa E and Carmignani L 2014 Extended-spectrum beta-lactamase-positive *Escherichia coli* causing complicated upper urinary tract infection: Urologist should act in time. *Urol. Ann.* 6: 107-112.
- Rajabnia M, Forghani MS, Hasani S, Bahadoram M, Mohammadi M and Barahman M 2019 Prevalence and antibiotic resistance pattern of extended

- spectrum beta lactamase producing *Escherichia coli* isolated from urinary tract infection. *J. Renal Inj. Prev.* 8(2): 78-81.
- Ramesh N, Sumathi CS, Balasubramanian V, Ravichandran KP and Kannan VR 2008 Urinary tract infection and antimicrobial susceptibility pattern of extended spectrum of beta lactamase producing clinical isolates. *Adv. Biol. Res.* 2(5-6): 78-82.
- Romero L, Lopez L, Rodriguez-Bano J, Hernandez JR, Martinez-Martinez L and Pascual A 2005 Long-term study of the frequency of *Escherichia coli* and *Klebsiella pneumoniae* isolates producing extended spectrum β -lactamases. *Clin. Microbiol. Infect.* 11: 625-631.
- Simner PJ, Zhanel GG, Pitou J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PRS, Adams HJ, Hoban DJ and Canadian Antimicrobial Resistance Alliance (CARA) 2011 Prevalence and characterization of extended-spectrum β -lactamase–and AmpC β -lactamase–producing *Escherichia coli*: results of the CANWARD 2007–2009 study. *Diagn. Microbiol. Infect. Dis.* 69(3): 326-334.
- Singh N, Pattnaik D, Neogi DK, Jena J and Mallick B 2016 Prevalence of ESBL in *Escherichia coli* isolates among ICU patients in a tertiary care hospital. *J. Clin. Diagn. Res.* 10: DC19- DC22.
- Tijjani J, Arzai AH and Sadiq NM 2012 Antimicrobial susceptibility pattern of extended spectrum beta lactamase producers in gram negative urogenital isolates in Kano, Nigeria. *Bayero J. Pure Appl. Sci.* 5(1): 20-25.
- Voets CM, Platteel TN, Fluit C, Scharringa J, Schapendonk CM, Stuart JC, Bonten JM and Hall MA 2012 Population distribution of beta-lactamase conferring resistance to third generation cephalosporins in human clinical Enterobacteriaceae in the Netherlands. *PLoS One* 7(12): e521202.
- Yadav K and Prakash 2017 Screening of ESBL producing multi-drug resistant *E. coli* from Urinary Tract Infection suspected cases in Southern Terai of Nepal. *J. Infect. Dis. Diagn.* 2(2):100116.